Table 1.
Guideline Author, Year | Country |
---|---|
American Diabetes Association, 2016 | United States |
American Association of Clinical Endocrinologist and American College of Endocrinology, 2016 |
United States |
National Institute for Health Excellence, 2015 | United Kingdom |
American Diabetes Association and the European Association for the Study of Diabetes, 2015 |
United States and Europe |
Royal Australian College of General Practitioners and Diabetes Australia, 2014–2015 |
Australia |
Health Technology Assessment Section Medical Development Division Ministry of Health Malaysia, 2015 |
Malaysia |
Joslin Diabetes Center Guidelines, 2014 | United States |
Institute for Clinical Systems Improvement Guidelines, 2014 |
United States |
Canadian Diabetes Association, 2013 | Canada |
Association Latinoamericana de Diabetes, 2013 | Multiples countries (approximately 30) |
Health Improvement Scotland, SIGN | Scotland |
The Japan Diabetes Society, 2013 | Japan |
International Diabetes Federation, 2012 | 160 Countries |
Society for Endocrinology, Metabolism and Diabetes of South Africa, 2012 |
South Africa |
Society of Endocrinology, Metabolism and Diabetes in South Africa, 2012 |
South Africa |
University of Michigan Health System, 2012 | United States |
Kidney Disease Outcomes Quality Initiative | United States |
Veterans Affairs Guideline and Department of Defense, 2010 |
United States |
All of the guidelines include a recommendation on hypoglycemia. Most guidelines state that a less stringent glucose goal should be considered (hemoglobin A1c, 7%–8% [to convert to proportion of hemoglobin, multiply by 0.01]) in patients with a history of severe hypoglycemia, limited life expectancy, advanced renal disease or macrovascular complications, extensive comorbid conditions, or long-standing diabetes mellitus in which the hemoglobin A1c goal has been difficult to attain despite intensive efforts as long as the patient remains free of polydipsia, polyuria, polyphagia, and other hyperglycemia-associated symptoms.